Clinical Outcome of COVID-19 Patients Presenting With Gastrointestinal Symptoms

Batool Abro  1, Jamil M. Bhatti  2, 3, Ali Akbar Siddiqui  4

1. Internal Medicine, Shaheed Mohtarma Benazir Bhutto Medical University, Larkana, PAK  2. Infectious Diseases, The Cancer Foundation Hospital, Karachi, PAK  3. Infectious Diseases, Dr. Ziauddin Hospital, Karachi, PAK  4. Gastroenterology and Hepatology, Isra University Hospital, Hyderabad, PAK

Corresponding author: Batool Abro, batool.abro@yahoo.com

Abstract

Background

Patients with coronavirus disease 2019 (COVID-19) usually have fever and respiratory tract complaints; however, many report gastrointestinal (GI) symptoms. The frequency of GI symptoms ranges from 16% to 61%. Although COVID-19 morbidity and mortality are related to pulmonary disease, poor outcomes have been linked to GI symptoms. Therefore, this study aimed to determine the outcomes of COVID-19 patients who presented with GI symptoms.

Methods

We conducted a retrospective cohort study at Isra University Hospital in Hyderabad, Pakistan, from April 2020 to October 2020.

Results

In total, 395 polymerase chain reaction-positive individuals were included. No differences in age or comorbidities were found. Of the 84 patients who needed intensive care unit admission, 17 had GI symptoms (P = 0.357). Moreover, GI symptoms were reported in 9/42 patients who required mechanical ventilation (P = 0.674) and 35/184 patients who required non-invasive ventilation (P = 0.029). GI symptoms were reported in 47/206 patients discharged on room air (without supplemental oxygen) (P = 0.549), 11/77 who died (P = 0.025), 2/11 who were referred elsewhere due to financial issues (P = 0.999), 7/32 who left against medical advice (P = 0.764), and 28/69 who were discharged requiring oxygen at home (P = 0.001).

Conclusions

Patients with GI symptoms had reduced odds of mortality, and increased odds of discharge requiring supplemental oxygen.

Introduction

The novel coronavirus identified in late 2019 was named the severe acute respiratory syndrome coronavirus 2 because of its structural similarity with the severe acute respiratory syndrome virus. In February 2020, its resulting disease was established as coronavirus disease 2019 (COVID-19)  [1]. Common presentations include fever and symptoms related to the respiratory tract; however, many COVID-19 patients report gastrointestinal (GI) symptoms. Different frequencies of GI symptoms have been reported worldwide, ranging from 16% to 61%  [2,3]. Pulmonary disease and thromboembolic phenomena are major causes of mortality and morbidity in patients with COVID-19, and studies have reported that some patients may present with GI symptoms, which may precede the development of pulmonary symptoms  [3,4]. To date, no study has been conducted on the outcomes of COVID-19 in patients with GI symptoms on presentation in Pakistan.

Materials And Methods

We conducted a retrospective cohort study at a tertiary care hospital in Pakistan from April 2020 to October 2020. The study included all polymerase chain reaction (PCR)-positive COVID-19 patients tested through a nasopharyngeal swab by reverse-transcription assay. Patients with two to three or more loose stools or vomiting, anorexia, and nausea within three to five days of testing were considered to have primary symptoms of interest. Death, discharge on room air (without oxygen [O2]), and discharged requiring O2 were considered outcomes of primary interest, while the need for intensive care unit (ICU) admission, non-
invasive ventilation, and assisted mechanical ventilation were outcomes of secondary interest. Other variables included age, gender, comorbidities, radiological findings, laboratory parameters, and other common symptoms of COVID-19. Patients who had a history of GI diseases or took any medication for GI symptoms were excluded. Institutional Review Board approval was obtained before conducting the study. We categorized discharged patients as those discharged on room air (without supplemental oxygen) and those who improved and were discharged anytime during their hospital stay requiring supplemental oxygen at home. Furthermore, those who could not stay due to financial issues were referred to other hospitals, and those who left against medical advice (LAMA) were labeled as such.

Data collection
We first collected a complete list of patients hospitalized with a diagnosis of PCR-positive COVID-19 through their electronic records. Demographics, clinical features, radiological findings, comorbidities, outcomes, and laboratory parameters were extracted through a detailed chart review. We also manually reviewed the patients’ charts for chief complaints and history of presenting illness to ensure accurate data capture. A total of 415 charts were reviewed, of which three were excluded because of a concomitant diagnosis of inflammatory bowel disease, two were excluded because of a concomitant diagnosis of irritable bowel syndrome, and 15 were excluded because of incomplete medical records.

Statistical analysis
We entered and analyzed the data using SPSS version 24 (IBM Corp, Armonk, NY, USA). We computed the median and interquartile range for continuous variables instead of mean and standard deviation; as data were not evenly distributed, when analysis was done, there was violation of the assumption of normality. Frequencies and percentages were computed for categorical variables, and their proportional differences were compared using the chi-squared test. Outcomes were computed using univariate and multivariate analyses. Kaplan-Meier analysis was performed to analyze patient survival. Statistical significance was set at $P < 0.05$.

Results
A total of 395 PCR-positive individuals were included. Hospital courses and demographic, clinical, and radiological characteristics are shown in Table 1.

|                         | Total | GI Symptoms n = 95 | No GI Symptoms n = 300 | P-Value |
|-------------------------|-------|--------------------|------------------------|---------|
| Age                     | 395   | 55.4 ± 13.7        | 55.8 ± 14.7            | 0.838   |
| Gender                  |       |                    |                        |         |
| Male                    | 266   | 71 (74.7%)         | 195 (65.0%)            | 0.078   |
| Female                  | 129   | 24 (25.3%)         | 105 (35.0%)            |         |
| Comorbidities           |       |                    |                        |         |
| Diabetes mellitus       | 194 (49.1%) | 49 (51.6%) | 145 (48.3%) | 0.581   |
| Hypertension            | 190 (48.1%) | 49 (51.6%) | 141 (47.0%) | 0.436   |
| CKD/ESRD                | 12 (3.0%) | 2 (2.1%)  | 10 (3.3%)  | 0.543   |
| Asthma                  | 28 (7.1%) | 9 (9.5%)  | 19 (6.4%)  | 0.299   |
| Ischemic heart disease  | 58 (14.7%) | 16 (16.8%) | 42 (14%)  | 0.495   |
| Chronic liver disease   | 7 (1.8%)  | 3 (3.2%)  | 4 (1.3%)  | 0.360*  |
| Malignancy              | 10 (2.5%)  | 2 (2.1%)  | 8 (2.7%)  | 0.999*  |
| Smoking                 | 45 (11.4%) | 11 (11.6%) | 34 (11.3%) | 0.948   |
| Symptoms                |       |                    |                        |         |
| Fever                   | 352 (89.1%) | 88 (92.6%) | 264 (88.0%) | 0.207   |
| Cough                   | 300 (75.9%) | 62 (65.3%) | 238 (79.3%) | 0.005   |
| Shortness of breath     | 309 (78.2%) | 63 (66.3%) | 246 (82.0%) | <0.001  |
| Lethargy                | 154 (38.9%) | 65 (68.4%) | 89 (29.7%) | <0.001  |
Myalgia 93 (23.5%) 35 (23.6%) 58 (19.3%) 0.001
Headache 57 (14.4%) 20 (14.1%) 58 (19.3%) 0.714
Anosmia 97 (24.6%) 28 (20.9%) 69 (23.0%) 0.201
Runny nose 47 (11.9%) 18 (14.8%) 29 (9.7%) 0.015
Hospital Course
ICU admission 84 (21.3%) 17 (17.9%) 67 (22.3%) 0.357
NIV 184 (46.6%) 35 (36.8%) 149 (49.7%) 0.029
Mechanical ventilation 42 (10.6%) 9 (9.5%) 33 (11.0%) 0.674
Radiological Findings
Bilateral infiltrates 272 (68.9%) 58 (61.1%) 214 (71.3%) 0.059
Peripheral infiltrates 277 (70.1%) 65 (68.4%) 212 (70.7%) 0.677
Ground glass opacities 96 (24.3%) 30 (31.6%) 66 (22.0%) 0.058
Consolidation 105 (26.6%) 23 (24.2%) 82 (27.3%) 0.548
Right lung involvement 322 (81.5%) 73 (76.8%) 249 (83.0%) 0.178
Left lung involvement 286 (72.4%) 60 (63.2%) 226 (75.3%) 0.021

TABLE 1: Demographic characteristics, features, radiologic findings, and hospital course of patients on presentation
CKD, chronic kidney disease; ESRD, end-stage renal disease; NIV, non-invasive ventilation; ICU, intensive care unit.
*Fisher’s exact test.

GI Symptoms
Anorexia 75 (19%)
Nausea 59 (14.9%)
Vomiting 40 (10.1%)
Diarrhea 70 (17.7%)

TABLE 2: GI symptoms of patients with coronavirus disease 2019 on presentation
GI, gastrointestinal.

Peripheral infiltrates were the most common radiological finding, with the right lung most commonly affected in our patient population. Other radiological findings included bilateral infiltrates, ground-glass opacities, and consolidation. Of the 84 patients who required ICU admission, 17 had GI symptoms (P = 0.357); of the 42 who required mechanical ventilation, nine had GI symptoms (P = 0.674); and of the 184 who were put on non-invasive ventilation, 35 had GI symptoms (P = 0.029). Baseline laboratory parameters are shown in Table 3.
GI symptoms were reported in 47/206 patients ultimately discharged without requiring O₂ at home (P = 0.549), 11/77 who died (P = 0.025), 2/11 who were referred to another facility due to financial issues (P = 0.999), 7/32 who LAMA (P = 0.765), and 28/69 who were discharged requiring O₂ at home (P = 0.001). On multivariable analysis (Table 5), patients who had GI symptoms on presentation had lower odds of death (odds ratio [OR], 0.464; P = 0.035), lower odds of requiring non-invasive ventilation (OR, 0.591; P = 0.029), and higher odds of requiring at-home O₂ therapy (OR, 2.640; P < 0.001). Furthermore, individuals with GI symptoms had lower odds of requiring invasive mechanical ventilation (OR, 0.847), requiring ICU admission (OR, 0.758), and having a severe disease (OR, 0.854) than individuals without GI symptoms, but these differences were not statistically significant (P = 0.675; P = 0.358; P = 0.604, respectively).

### TABLE 3: Baseline laboratory parameters

| Parameter                        | GI Symptoms Median (IQR) n = 95 | No GI Symptoms Median (IQR) n = 300 | P-Value |
|----------------------------------|---------------------------------|-------------------------------------|---------|
| White blood cells (×10⁹/L)       | 9.0 (7.0-13.0)                  | 11.0 (8.0-17.0)                     | 0.005   |
| Hemoglobin (g/dL)                | 12 (11-13)                      | 12 (11-13)                          | 0.939   |
| Lymphocytes (%)                  | 15 (7-25)                       | 10 (5-19)                           | 0.005   |
| Platelets (×10⁹/L)               | 273 (177-343)                   | 238 (175-330)                       | 0.337   |
| ALT (U/L)                        | 44 (25-70)                      | 40 (27-65)                          | 0.973   |
| AST (U/L)                        | 50 (34-78)                      | 45 (31-65)                          | 0.258   |
| Creatinine (mg/dL)               | 1.0 (0.9-1.0)                   | 1.0 (1.0-1.2)                       | 0.002   |
| D-dimer (ng/mL FEU)              | 1073 (527-2938)                 | 1819 (773-7647)                     | 0.005   |
| LDH (U/L)                        | 408 (296-562)                   | 445 (320-653)                       | 0.120   |
| C-reactive protein               | 98 (39-189)                     | 98 (39-189)                         | 0.749   |
| Serum ferritin (ng/mL)           | 915 (500-1451)                  | 758 (356-1463)                      | 0.158   |

GI, gastrointestinal; ALT, alanine transaminase; AST, aspartate transaminase; LDH, lactate dehydrogenase, IQR, interquartile range; FEU, fibrinogen-equivalent units.

On presentation, those with GI symptoms had a significantly lower median white cell count (9.0 × 10⁹ vs. 11 × 10⁹/L; P = 0.005), lower lymphopenia prevalence (15% vs. 10%; P = 0.005), and lower D-dimer (1073 vs. 1819 ng/mL; P = 0.005) than those without GI symptoms; lactate dehydrogenase (408 vs. 445 U/L; P = 0.120) and other inflammatory markers, such as serum ferritin, were not significantly different between groups. Patient outcomes are shown in Table 4.

### TABLE 4: Outcome of patients

| Outcome                  | GI Symptoms n = 95 | No GI Symptoms n = 300 | P-Value |
|--------------------------|--------------------|------------------------|---------|
| Discharged on RA         | 47 (49.5%)         | 159 (53.0%)            | 0.549   |
| Expired                  | 11 (11.6%)         | 66 (22.0%)             | 0.025   |
| Referred                 | 2 (2.1%)           | 9 (3.0%)               | 0.999*  |
| LAMA                     | 7 (7.4%)           | 25 (8.3%)              | 0.765   |
| Discharged on O₂         | 28 (29.5%)         | 41 (13.7%)             | 0.001   |

GI, gastrointestinal; RA, room air; LAMA, left against medical advice; O₂, oxygen.

*Fisher’s exact test.
|                | Odds Ratio | 95% CI          | P-Value |
|----------------|------------|-----------------|---------|
| Gender         | 0.628      | 0.373-1.056     | 0.078   |
| Expired        | 0.464      | 0.234-0.921     | 0.035   |
| Discharged on RA | 0.868     | 0.547-1.378     | 0.550   |
| Discharged on O₂ | 2.640   | 1.522-4.578     | <0.001  |
| IMV            | 0.847      | 0.390-1.840     | 0.675   |
| NIV            | 0.591      | 0.368-0.950     | 0.029   |
| ICU admission  | 0.758      | 0.420-1.368     | 0.358   |
| Severe disease | 0.854      | 0.471-1.549     | 0.604   |
| Critical disease | 0.527  | 0.214-1.298     | 0.159   |

**TABLE 5: Multivariate analysis of GI symptoms**

CI, confidence interval; IMV, invasive mechanical ventilation; NIV, non-invasive ventilation; ICU, intensive care unit; RA, room air; O₂, oxygen.

**Discussion**

COVID-19 has posed extraordinary challenges to global healthcare systems. The majority of patients present with fever, lethargy, or pulmonary manifestations; however, almost all organs of the body can be involved, and GI symptoms are among those commonly reported [5]. Moreover, viral shedding in the feces of patients has been reported in the literature worldwide [6]. In early 2020, many patients with GI symptoms were overlooked by clinicians, resulting in the transmission of infection to other patients and increased morbidity and mortality as a result of late diagnosis [3].

Here, we found no differences in mean age between the two groups. There was also no significant difference in comorbidities, which contradicts the findings of Laszkowska et al. [7]. This study concluded that 24.1% of patients included here had GI symptoms. This prevalence was lower than that reported by some studies from China and the USA, which described figures ranging from 50.5% to 61.3% [8,9]. However, this prevalence was higher than the 10.3% prevalence reported by a study in India [10], as well as the 17.6% prevalence reported by a meta-analysis of >59 studies and >4000 patients [11]. A lower prevalence of GI symptoms has also been observed in the USA in a recent meta-analysis of >10,000 patients and another of >8000 patients; these studies reported a prevalence of 7.8% [12] and 10% [13], respectively. Anorexia was found to be the most common GI symptom in our study; when we excluded anorexia, only 19% of patients had GI symptoms, as some identified anorexia as a non-specific complaint found in many other conditions. This study reported diarrhea in 17.7% of patients, nausea in 14.9%, and vomiting in 10.1%; this was inconsistent with findings of one American study that reported diarrhea and nausea in 33% and 26.4% of patients, respectively [2], as well as with those from a meta-analysis that reported diarrhea in 7.4% of patients and nausea or vomiting in 4.6% [14].

This study found significant differences in the outcomes of patients with GI symptoms on presentation. A significant association was found between the presentation of GI symptoms and lower mortality; patients with GI symptoms had lower mortality rates than those without. Furthermore, patients were more likely to be discharged requiring supplemental O₂ if they had GI symptoms on presentation. This finding is not consistent with the findings of Ramchandran et al. and Redd et al., who found no association between GI symptoms and worse clinical outcomes of COVID-19 [2,15]. However, Pan et al. concluded that COVID-19 patients with GI symptoms had lower recovery and discharge rates than those without GI symptoms [16]. Other studies have reported significant associations between poor outcomes, more severe illness, and GI symptoms [4,8]. Significant associations have been found in other studies [17,18]. This study’s findings are consistent with those of Laszkowska et al., who found better outcomes in COVID-19 patients with GI symptoms, including lower rates of mortality and lower rates of requiring mechanical ventilation [7].

This study reported that COVID-19 patients with GI symptoms had significantly lower D-dimer levels than those without such symptoms, while serum ferritin, lactate dehydrogenase, and C-reactive protein levels were not significantly different. In contrast, Laszkowska et al. demonstrated lower C-reactive protein and other markers, including D-dimer and lactate dehydrogenase levels [7]. In one multicenter study, Zhou et al. also found elevated C-reactive protein levels in COVID-19 patients with GI symptoms [19]. Moreover, this study found a significant difference in lymphocyte count between the two groups; COVID-19 patients with GI symptoms had a higher median lymphocyte count than those without GI symptoms. In contrast, Chen et
al. reported a negative relationship between circulating lymphocyte count and initial GI symptoms [20].

One important strength of our study is the validation of our results from other studies by Laszkowska et al. [7]. Additionally, to the best of our knowledge, this is the first study from Pakistan to evaluate outcomes of patients with GI symptoms on presentation.

This study has a few limitations, including its retrospective design, that it was a single-center study with a small sample size, and its reliance on medical records rather than direct patient histories. This could result in selection bias and limit the generalizability of the results. Another limitation of this study was the inclusion of only hospitalized patients, which does not reflect the true prevalence and outcome of COVID-19 patients with GI symptoms.

Conclusions

This study concluded that COVID-19 patients with GI symptoms on presentation had decreased odds of mortality, and increased odds of discharge requiring supplemental oxygen. Inflammatory markers were lower in patients with GI symptoms, which may be a possible cause of indolent disease in these patients. Further data are required to confirm this association.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Isra University Ethical Research Committee issued approval IUH/ASST DEAN (CS)/02/50. There is no ethical issue involved in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. WHO Director-General’s Remarks at the Media Briefing on 2019-nCoV on 11 February 2020 . Accessed: June 16, 2021: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february....
2. Redd WD, Zhou JC, Harthorn KE, et al.: Prevalence and characteristics of gastrointestinal symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection in the United States: a multicenter cohort study. Gastroenterology. 2020, 159:765-767.e2. 10.1053/j.gastro.2020.04.045
3. Luo S, Zhang X, Xu H: Don’t overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19). Clin Gastroenterol Hepatol. 2020, 18:1656-7. 10.1016/j.cgh.2020.05.043
4. Jin X, Lian JS, Hu JH, et al.: Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020, 69:1002-9. 10.1136/gutjnl-2020-320926
5. Zhu N, Zhang D, Wang W, et al.: A novel coronavirus from patients with pneumonia in China, 2019 . N Engl J Med. 2020, 382:727-33. 10.1056/NEJMoA2001017
6. Holshue ML, DeBolt C, Lindquist S, et al.: First case of 2019 novel coronavirus in the United States . N Engl J Med. 2020, 382:929-36. 10.1056/NEJMoA2001191
7. Laszkowska M, Faye AS, Kim J, et al.: Disease course and outcomes of COVID-19 among hospitalized patients with gastrointestinal manifestations. Clin Gastroenterol Hepatol. 2020, 18:1542-566(20)31567-7. 10.1016/j.cgh.2020.09.037
8. Pan L, Mu M, Yang P, et al.: Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020, 115:766-73. 10.14309/aig.0000000000000620
9. Nobel YR, Phipps M, Zucker J, Lebowohl B, Wang TC, Sobieszczynk ME, Freedberg DE: Gastrointestinal symptoms and coronavirus disease 2019: a case–control study from the United States. Gastroenterology. 2020, 159:573-575.e2. 10.1053/j.gastro.2020.04.017
10. Ghoshal UC, Ghoshal U, Mathur A, et al.: The spectrum of gastrointestinal symptoms in patients with coronavirus disease-19: predictors, relationship with disease severity, and outcome. Clin Transl Gastroenterol. 2020, 11:e00259. 10.14309/ctg.0000000000000259
11. Cheung KS, Hung IFN, Chan PPY, et al.: Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterology. 2020, 159:81-95. 10.1053/j.gastro.2020.05.065
12. Sultan S, Altayar O, Siddique SM, et al.: AGA Institute rapid review of the gastrointestinal and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology. 2020, 159:320-334.e27. 10.1053/j.gastro.2020.05.001
13. Kumar A, Arora A, Sharma P, et al.: Gastrointestinal and hepatic manifestations of corona virus disease-19 and their relationship to severe clinical course: a systematic review and meta-analysis. Indian J Gastroenterol. 2020, 39:268-84. 10.1007/s12664-020-01058-3
14. Parasa S, Desai M, Thoguluva Chandrasekar V, et al.: Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: a systematic review and meta-analysis. JAMA Netw Open. 2020, 3:e2011335. 10.1001/jamanetworkopen.2020.11355
15. Ramachandran P, Onukogu I, Ghuanta S, Gajendran M, Perisetti A, Goyal H, Aggarwal A: Gastrointestinal symptoms and outcomes in hospitalized coronavirus disease 2019 patients. Dig Dis. 2020, 38:373-9. 10.1159/000509774
16. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q: Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020, 20:411-2. 10.1016/S1473-3099(20)30115-4
17. Colaneri M, Sacchi P, Zuccaro V, et al.: Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Euro Surveill. 2020, 25:2000460. 10.2807/1560-7917.ES.2020.25.16.2000460
18. Aggarwal S, Garcia-Telles N, Aggarwal G, Lavi C, Lippi G, Henry BM: Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States. Diagnosis (Berl). 2020, 7:91-6. 10.1515/dx-2020-0046
19. Zhou F, Yu T, Du R, et al.: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395:1054-62. 10.1016/S0140-6736(20)30566-3
20. Chen W, Zheng KI, Liu S, Xu C, Xing C, Qiao Z: Virus discharge and initial gastrointestinal involvement are inversely associated with circulating lymphocyte count in COVID-19. Int J Med Sci. 2021, 18:1137-42. 10.7150/ijms.51672